Ontology highlight
ABSTRACT:
SUBMITTER: Rodon J
PROVIDER: S-EPMC6286256 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Rodon Jordi J Pérez-Fidalgo Alejandro A Krop Ian E IE Burris Howard H Guerrero-Zotano Angel A Britten Carolyn D CD Becerra Carlos C Schellens Jan J Richards Donald A DA Schuler Martin M Abu-Khalaf Maysa M Johnson Faye M FM Ranson Malcolm M Edenfield Jeff J Silva Antonio P AP Hackl Wolfgang W Quadt Cornelia C Demanse David D Duval Vincent V Baselga Jose J
Cancer chemotherapy and pharmacology 20180607 2
<h4>Purpose</h4>To determine the maximum tolerated dose (MTD) of BEZ235, an oral inhibitor of class I PI3K and mTOR complexes 1 and 2.<h4>Methods</h4>We performed a phase I/Ib, multicenter, open-label study of oral BEZ235 administered in a continuous daily schedule. The study consisted of two parts: dose-escalation part and safety-expansion part. BEZ235 was administered as a single agent to patients with solid tumors or in combination with trastuzumab for HER2+ advanced breast cancer (aBC). Prim ...[more]